Physician profile
Mark Callow
NPI 1457644338
$35,548.70
in general payments reported to CMS, 2019-2025
22 companies · $3,130 in 2025
The $3,130 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $858 · 2021: $814 · 2022: $5,622 · 2023: $8,526 · 2024: $4,654 · 2025: $3,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,202 · Honoraria: $1,350 · Consulting Fee: $720 · Travel and Lodging: $17.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,020.00 |
| Food and Beverage | $3,202.33 |
| Honoraria | $1,350.00 |
| Consulting Fee | $720.00 |
| Travel and Lodging | $17.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $17,459.59 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Sunovion Pharmaceuticals INC. | $7,282.43 | 2019-2021 | |
| Livanova USA, INC. | $4,013.11 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Catalyst Pharmaceuticals, INC. | $1,817.36 | 2023-2025 | Fycompa |
| Sk Life Science, INC. | $1,592.60 | 2020-2025 | Xcopri |
| Supernus Pharmaceuticals, INC. | $702.71 | 2019-2022 | |
| Eisai INC. | $552.13 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $533.59 | 2020-2025 | |
| Neurelis, INC. | $501.58 | 2020-2025 | Valtoco |
| Greenwich Biosciences, INC. | $423.40 | 2019-2021 | |
| Biogen, INC. | $237.05 | 2019-2023 | Tysabri |
| Neuropace, INC. | $125.40 | 2024 | |
| Neurocrine Biosciences, INC. | $60.41 | 2022 | |
| Aucta Pharmaceuticals, INC. | $59.01 | 2025 | Motpoly Xr |
| Alexion Pharmaceuticals, INC. | $35.84 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $33.25 | 2019 | |
| Amgen INC. | $25.59 | 2025 | Uplizna |
| Mallinckrodt Enterprises LLC | $21.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.21 | 2021 | |
| Lilly USA, LLC | $20.49 | 2023 | Amyvid |
| Sumitomo Pharma America, INC. | $15.91 | 2023 | Aptiom |
| Aprecia Pharmaceuticals, LLC | $14.83 | 2023 | Spritam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Callow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.